If you have been reading about GIP receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
The physiological role for responses to these, and several other glycoprotein hormones, is not fully understood, although it is likely that ACTH is bifunctional, like PTH, supporting bone formation with periodic spikes of ACTH, but causing bone destruction in large concentrations. In mice, mutations that reduce the efficiency of ACTH-induced glucocorticoid production in the adrenals cause the skeleton to become dense (osteosclerotic bone).
== External links == GeneReviews/NCBI/NIH/UW entry on COL4A1-Related Disorders - Autosomal Dominant Type 1 Porencephaly; Brain Small Vessel Disease with Hemorrhage; Hereditary Angiopathy with Nephropathy, Aneurysms, and Muscle Cramps
Only promethium-147 has uses outside laboratories. It is obtained as the oxide or chloride, in milligram quantities. This isotope has a relatively long half-life and its radiation has a relatively small penetration depth in matter. Some signal lights use a luminous paint containing a phosphor that absorbs the beta radiation emitted by promethium-147 and emits light. This isotope does not cause aging of the phosphor, as alpha emitters do, and therefore the light emission is stable for a few years. Originally, radium-226 was used for the purpose, but it was later replaced by promethium-147 and tritium (hydrogen-3). Promethium may be favored over tritium for nuclear safety. In atomic batteries, the beta particles emitted by promethium-147 are converted into electric current by sandwiching a small promethium source between two semiconductor plates. These batteries have a useful lifetime of about five years. The first promethium-based battery was assembled in 1964 and generated "a few milliwatts of power from a volume of about 2 cubic inches, including shielding". Promethium is also used to measure the thickness of materials by measuring the amount of radiation from a promethium source that passes through the sample. It has possible future uses in portable X-ray sources, and as auxiliary heat or power sources for space probes and satellites (although the alpha emitter plutonium-238 has become standard for most space-exploration-related uses).
=== Creation of Drug Enforcement Agency === In 1973, Nixon created the Drug Enforcement Agency (DEA) to bring together the Bureau of Dangerous Drugs and the US Customs Agency. According to the DEA's own historical record, the goal of the merger was to end the rivalry and the miscommunication between the offices in an attempt to combat the rising availability and use of drugs in the US. Upon its creation, the DEA received a $1 billion increase in federal funding over what the two agencies had been receiving prior to the merger. From 1973, before the merger, to 1974, federal budgeting for drug enforcement rose $41 billion and would increase again in 1975 from $116.20 billion to $140.90 billion.
Drew was born in 1904 into an African-American middle-class family in Washington, D.C. His father, Richard, was a carpet layer, and his mother, Nora Burrell, trained as a teacher. Drew and three (two sisters, one brother) of his four younger siblings (three sisters and one brother) grew up in Washington's largely middle-class and interracial Foggy Bottom neighborhood. From a young age Drew began work as a paperboy in his neighborhood, daily helping deliver over a thousand newspapers to his neighbors. Drew attended Washington's Dunbar High School which was well-known for its equality and opportunities for all, despite the racial climate at the time. From 1920 until his marriage in 1939, Drew's permanent address was in Arlington County, Virginia, although he graduated from Washington's Dunbar High School in 1922 and resided elsewhere during that period of time.
Sources: en.wikipedia.org
Redox ( RED-oks, REE-doks, reduction–oxidation or oxidation–reduction) is a type of chemical reaction in which the oxidation states of the reactants change. Oxidation is the loss of electrons or an increase in the oxidation state. Reduction is the gain of electrons or a decrease in the oxidation state. The oxidation and reduction processes occur simultaneously in the chemical reaction. Redox reactions fall into two classes. In electron transfer, a single electron usually flows from the atom, ion, or molecule being oxidized to the one being reduced; this is often described in terms of redox couples and electrode potentials. In atom transfer, an atom passes from one substrate to another; for example, in the rusting of iron the oxidation state of the iron atoms increases as the metal converts to an oxide and oxygen is reduced as it absorbs the released electrons. Redox reactions occur throughout nature and industry. Cellular respiration and photosynthesis, combustion, and the corrosion of metals all proceed through redox chemistry, as do the reactions that power batteries and other electrochemical cells. Industry uses redox reactions to extract metals from their ores by smelting, to electroplate objects, and to manufacture chemicals such as nitric acid. In soils, sediments, and water, redox gradients drive the biogeochemical cycling of elements.
== See also == Ballistic nylon – Thick, tough, nylon fabric Cordura – Brand of high-performance fabrics developed by DuPont and now owned by Invista Forensic engineering – Investigation of failures associated with legal intervention Nylon-eating bacteria – Species of bacteria Polyamide – Macromolecule with repeating units linked by amide bonds Ripstop nylon – Reinforced woven fabricPages displaying short descriptions of redirect targets Step-growth polymerization – Type of polymerization reaction mechanism
== Modifications == Serpin A12 has three possible glycosylation sites located at asparagine residues. These can be post-translational modifications that may change the protein's properties. Although the protein can undergo these different glycosylation processes, they only diminish heparin affinity. There is no significant effect on KLK7 activity or the protein's thermal stability.
=== Nanoparticles === A novel application for gel electrophoresis is the separation or characterization of metal or metal oxide nanoparticles (e.g. Au, Ag, ZnO, SiO2) regarding the size, shape, or surface chemistry of the nanoparticles. The scope is to obtain a more homogeneous sample (e.g. narrower particle size distribution), which then can be used in further products/processes (e.g. self-assembly processes). For the separation of nanoparticles within a gel, the key parameter is the ratio of the particle size to the mesh size, whereby two migration mechanisms were identified: the unrestricted mechanism, where the particle size << mesh size, and the restricted mechanism, where particle size is similar to mesh size.
Sources: en.wikipedia.org
=== Animal rights === In 2005, 2008, and 2010 PETA threatened to submit a shareholder resolution to improve animal welfare standards in the company. In 2005, PETA attempted to stop five specific animal experiments that it deemed "crude and cruel". In 2008, PETA protested the outsourcing of animal testing to countries with lax animal welfare laws, such as China. In 2010, PETA attempted to stop Medtronic's reported use of live animals in testing and training. In response, Medtronic conducted a feasibility study that found that banning the use of live animals was impractical. As of 2015 Medtronic continued to use live animals for testing and training but stated that it would look for alternatives in the future. In each case, PETA withdrew its shareholder resolution after talks with Medtronic's leadership.
These included statements that God emits a cosmic broadcast of electromagnetic waves that living creatures can receive when their neural networks are enabled by DMT; that adding DMT allows people to see otherwise invisible spirits and guardian angels; that schizophrenia and autism result from an over-abundance of bioavailable DMT and should be unified under the term “Autiphrenia,” with those affected described as geniuses created to lead humanity; that vaporizing DMT had cured his brain cancer; that staring at the sun promotes DMT production in the pineal gland; and that DMT could cure other diseases. He invited cancer patients to his ranch in the Lake View Terrace area of Los Angeles to try the substance. In a video recorded after the cancer claim was questioned, Cantelmo stated that he had never had any form of cancer and that the reference was metaphorical, describing atheism as the “worst form of cancer.” His brother Craig and other family members confirmed he had never been diagnosed with cancer.
=== Doping === As of 2007, it was widely reported that tetracosactide had been used as an illegal performance-enhancing drug by professional cyclists. It is known to be used as a doping agent to increase the secretion of glucocorticoids by adrenal glands.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.